TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING GERIATRIC POPULATION
4.2.2 GROWING PREVALENCE OF GEOGRAPHIC ATROPHY
4.3 RESTRAINTS
4.3.1 LACK OF AVAILABILITY OF GEOGRAPHIC ATROPHY TREATMENT
4.4 OPPORTUNITIES
4.4.1 RISING R&D INVESTMENTS BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL GEOGRAPHIC ATROPHY MARKET
5.3.1 IMPACT ON MAKET GROWTH
5.3.2 IMPACT ON PATIENTS WITH GEOGRAPHIC ATROPHY
5.3.3 IMPACT ON R&D
6 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP
6.1 OVERVIEW
6.2 LESS THAN 65 YEARS
6.3 65-74 YEARS
6.4 75-84 YEARS
6.5 85 YEARS AND ABOVE
7 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS
7.1 OVERVIEW
7.2 FUNDUS AUTOFLUORESCENCE (FAF)
7.3 OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY (OCT-A)
7.4 MULTIFOCAL ELECTRORETINOGRAPHY (MFERG)
8 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE
8.1 OVERVIEW
8.2 LATE-STAGE (PHASE III)
8.3 PHASE II
8.4 PHASE I
8.5 PRE-CLINICAL STAGE & DISCOVERY CANDIDATES
9 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY REGION
9.1 OVERVIEW
9.2 AMERICAS
9.2.1 NORTH AMERICA
9.2.1.1 US
9.2.1.2 CANADA
9.2.1.3 MEXICO
9.2.2 CENTRAL & SOUTH AMERICA
9.2.2.1 BRAZIL
9.2.2.2 ARGENTINA
9.2.2.3 CHILE
9.2.2.4 REST OF CENTRAL & SOUTH AMERICA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 NETHERLANDS
9.3.7 DENAMARK
9.3.8 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 TAIWAN
9.4.7 REST OF ASIA-PACIFIC
9.5 MIDDLE EAST AND AFRICA
9.5.1 UAE
9.5.2 SAUDI ARABIA
9.5.3 SOUTH AFRICA
9.5.4 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GEOGRAPHIC ATROPHY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GEOGRAPHIC ATROPHY MARKET
10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.5.1 PRODUCT LAUNCH/PRODUCT APPROVAL
10.5.2 MERGER/ACQUISITION
10.6 MAJOR PLAYERS SALES ANALYSIS
10.6.1 SALES & OPERATING INCOME
10.6.2 MAJOR PLAYERS R&D ANALYSIS
11 COMPANY PROFILES
11.1 F. HOFFMANN-LA ROCHE AG
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 APELLIS PHARMACEUTICALS
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 IVERIC BIO, INC.
11.3.1 COMPANY OVERVIEWS
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 ALKEUS PHARMACEUTICALS
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 HEMERA BIOSCIENCES LLC
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 NGM BIOPHARMACEUTICALS
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 JOHNSON & JOHNSON SERVICES, INC
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 ASTRAZENECA
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 NOVARTIS AG
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 STEALTH BIOTHERAPEUTICS CORP
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 3 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR LESS THAN 65 YEARS, BY REGION, 2019–2030 (USD MILLION)
TABLE 4 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR 65-74 YEARS, BY REGION, 2019–2030 (USD MILLION)
TABLE 5 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR 75-84 YEARS, BY REGION, 2019–2030 (USD MILLION)
TABLE 6 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR 85 YEARS AND ABOVE, BY REGION, 2019–2030 (USD MILLION)
TABLE 7 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 8 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR FUNDUS AUTOFLUORESCENCE (FAF), BY REGION, 2019–2030 (USD MILLION)
TABLE 9 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY (OCT-A), BY REGION, 2019–2030 (USD MILLION)
TABLE 10 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR MULTIFOCAL ELECTRORETINOGRAPHY (MFERG), BY REGION, 2019–2030 (USD MILLION)
TABLE 11 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 12 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR LATE-STAGE (PHASE III), BY REGION, 2019–2030 (USD MILLION)
TABLE 13 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR PHASE II, BY REGION, 2019–2030 (USD MILLION)
TABLE 14 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR PHASE I, BY REGION, 2019–2030 (USD MILLION)
TABLE 15 GLOBAL GEOGRAPHIC ATROPHY MARKET, FOR PRE-CLINICAL STAGE & DISCOVERY CANDIDATES, BY REGION, 2019–2030 (USD MILLION)
TABLE 16 GLOBAL: GEOGRAPHIC ATROPHY MARKET, BY REGION, 2019–2030 (USD MILLION)
TABLE 17 AMERICAS: GEOGRAPHIC ATROPHY MARKET, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 18 AMERICAS: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 19 AMERICAS: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 20 AMERICAS: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 21 NORTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 22 NORTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 23 NORTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 24 NORTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 25 US: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 26 US: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 27 US: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 28 CANADA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 29 CANADA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 30 CANADA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 31 MEXICO: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 32 MEXICO: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 33 MEXICO: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 34 CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 35 CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 36 CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 37 CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 38 BRAZIL: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 39 BRAZIL: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 40 BRAZIL: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 41 ARGENTINA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 42 ARGENTINA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 43 ARGENTINA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 44 CHILE: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 45 CHILE: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 46 CHILE: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 47 REST OF CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 48 REST OF CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 49 REST OF CENTRAL & SOUTH AMERICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 50 EUROPE: GEOGRAPHIC ATROPHY MARKET, BY REGION, 2019–2030 (USD MILLION)
TABLE 51 EUROPE: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 52 EUROPE: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 53 EUROPE: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 54 GERMANY: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 55 GERMANY: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 56 GERMANY: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 57 FRANCE: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 58 FRANCE: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 59 FRANCE: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 60 UK: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 61 UK: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 62 UK: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 63 ITALY: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 64 ITALY: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 65 ITALY: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 66 SPAIN: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 67 SPAIN: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 68 SPAIN: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 69 NETHERLANDS: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 70 NETHERLANDS: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 71 NETHERLANDS: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 72 DENAMARK: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 73 DENAMARK: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 74 DENAMARK: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 75 REST OF EUROPE: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 76 REST OF EUROPE: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019–2030 (USD MILLION)
TABLE 77 REST OF EUROPE: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT'S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 82 CHINA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 83 CHINA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 84 CHINA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 85 INDIA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 86 INDIA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 87 INDIA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 88 JAPAN: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 89 JAPAN: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 90 JAPAN: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 91 SOUTH KOREA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 92 SOUTH KOREA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 93 SOUTH KOREA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 94 AUSTRALIA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 95 AUSTRALIA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 96 AUSTRALIA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 97 TAIWAN: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 98 TAIWAN: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 99 TAIWAN: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 100 REST OF ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 101 REST OF ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 102 REST OF ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 105 MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 106 MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 107 UAE: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 108 UAE: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 109 UAE: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 110 SAUDI ARABIA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 111 SAUDI ARABIA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 113 SOUTH AFRICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 114 SOUTH AFRICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 115 SOUTH AFRICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 116 REST OF MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2019–2030 (USD MILLION)
TABLE 117 REST OF MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2019-2030 (USD MILLION)
TABLE 118 REST OF MIDDLE EAST & AFRICA: GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2019–2030 (USD MILLION)
TABLE 119 MAJOR PLAYERS IN THE GLOBAL GEOGRAPHIC ATROPHY MARKET
TABLE 120 MOST ACTIVE PLAYER IN THE GLOBAL GEOGRAPHIC ATROPHY MARKET
TABLE 121 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 122 MERGER/ACQUISITION
TABLE 123 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED
TABLE 124 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 125 APELLIS PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 126 IVERIC BIO, INC.: PRODUCTS OFFERED
TABLE 127 IVERIC BIO, INC.: KEY DEVELOPMENTS
TABLE 128 ALKEUS PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 129 HEMERA BIOSCIENCES LLC: PRODUCTS OFFERED
TABLE 130 NGM BIOPHARMACEUTICALS: PRODUCTS OFFERED
TABLE 131 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED
TABLE 132 ASTRAZENECA: PRODUCTS OFFERED
TABLE 133 ASTRAZENECA: KEY DEVELOPMENTS
TABLE 134 NOVARTIS AG: PRODUCTS OFFERED
TABLE 135 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 136 STEALTH BIOTHERAPEUTICS INC: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL GEOGRAPHIC ATROPHY MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GEOGRAPHIC ATROPHY MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL GEOGRAPHIC ATROPHY MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GEOGRAPHIC ATROPHY MARKET
FIGURE 9 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY AGE GROUP, 2022 & 2030 (USD MILLION)
FIGURE 11 GLOBAL GEOGRAPHIC ATROPHY MARKET SHARE, BY AGE GROUP, 2022 (%)
FIGURE 12 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 13 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY DIAGNOSIS, 2022 & 2030 (USD MILLION)
FIGURE 14 GLOBAL GEOGRAPHIC ATROPHY MARKET SHARE, BY DIAGNOSIS, 2022 (%)
FIGURE 15 GLOBAL GEOGRAPHIC ATROPHY MARKET; THERAPEUTIC AGENT’S CLINICAL PHASE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 16 GLOBAL GEOGRAPHIC ATROPHY MARKET, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2022 & 2030 (USD MILLION)
FIGURE 17 GLOBAL GEOGRAPHIC ATROPHY MARKET SHARE, BY THERAPEUTIC AGENT’S CLINICAL PHASE, 2022 (%)
FIGURE 18 GLOBAL: GEOGRAPHIC ATROPHY MARKET SHARE (%), BY REGION, 2022
FIGURE 19 AMERICAS MARKET ANALYSIS: GEOGRAPHIC ATROPHY MARKET, 2019-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA: GEOGRAPHIC ATROPHY MARKET SHARE (%), BY REGION 2022
FIGURE 21 EUROPE MARKET ANALYSIS: GEOGRAPHIC ATROPHY MARKET, 2019-2030 (USD MILLION)
FIGURE 22 EUROPE: GEOGRAPHIC ATROPHY MARKET SHARE (%), BY REGION 2022
FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: GEOGRAPHIC ATROPHY MARKET, 2019-2030 (USD MILLION)
FIGURE 24 ASIA-PACIFIC: GEOGRAPHIC ATROPHY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 25 MIDDLE EAST & AFRICA MARKET ANALYSIS: GEOGRAPHIC ATROPHY MARKET, 2019-2030 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA: GEOGRAPHIC ATROPHY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 27 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 28 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL GEOGRAPHIC ATROPHY MARKET
FIGURE 29 MAJOR PLAYERS SALES & OPERATING INCOME, 2022
FIGURE 30 MAJOR PLAYER R&D EXPENDITURE, 2022
FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 F. HOFFMANN-LA ROCHE AG: SWOT ANALYSIS
FIGURE 33 APELLIS PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 APELLIS PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 35 NGM BIOPHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 NGM BIOPHARMACEUTICALS: SWOT ANALYSIS
FIGURE 37 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
FIGURE 39 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 ASTRAZENECA: SWOT ANALYSIS
FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
